Decision-Making Challenges Post-Immunotherapy in dMMR/MSI Metastatic Colorectal Cancer

Overview

Immunotherapy with immune checkpoint inhibitors (ICI) has revolutionized treatment for metastatic colorectal cancer (mCRC) with deficient mismatch repair (dMMR) and microsatellite instability (MSI), showing unprecedented efficacy and potential cure. Key clinical challenges include determining optimal treatment duration and managing residual tumor masses after response to immunotherapy.

Background

Approximately 5% of metastatic colorectal cancers exhibit dMMR/MSI, characterized by high immunogenicity and genomic hypermutation. Immune checkpoint inhibitors, particularly the combination of ipilimumab and nivolumab, have become the new standard first-line treatment, replacing chemobiotherapy. Despite excellent outcomes, questions remain regarding how long to continue immunotherapy and how to approach residual lesions post-treatment, given their atypical pathological features compared to conventional chemotherapy responses.

Data Highlights

Key Findings

• ICI treatment for dMMR/MSI mCRC yields durable disease control and potential cure, outperforming standard chemotherapy.
• Optimal ICI treatment duration is unclear; evidence suggests shorter durations (around 7-12 months) may be as effective as the conventional 2-year course.
• Residual masses post-immunotherapy often represent necrosis, fibrosis, and immune infiltration rather than viable tumor, complicating radiological assessment.
• Conventional imaging lacks specificity to distinguish between complete pathological response and residual active disease.
• Biomarkers such as tumor markers (CEA, CA-19.9) and circulating tumor DNA (ctDNA) may aid in monitoring and decision-making.
• Unnecessary surgical resection of non-viable residual lesions may cause morbidity without benefit; surveillance may be appropriate in selected patients.

Clinical Implications

Clinicians should consider that prolonged immunotherapy beyond one year may not always be necessary, potentially reducing toxicity and healthcare costs without compromising efficacy. Careful assessment combining clinical symptoms, tumor markers, advanced imaging, and possibly ctDNA is essential before deciding on surgical intervention for residual lesions. Prospective trials are needed to establish evidence-based guidelines for treatment duration and management of residual disease.

Conclusion

Immune checkpoint inhibitors have transformed the management of dMMR/MSI metastatic colorectal cancer, offering durable responses and potential cures. Future research should focus on optimizing treatment duration and refining diagnostic tools to guide management of residual lesions, minimizing unnecessary interventions.

References

1. CheckMate 8HW Trial 2024 -- Dual Immunotherapy in dMMR/MSI mCRC
2. NIPICOL Phase II Trial -- 1-Year ICI Treatment Outcomes
3. Taieb et al. Retrospective Series -- ICI Duration and Survival
4. Pathological Analysis of Residual Tumors Post-ICI
5. Role of ctDNA in Monitoring dMMR/MSI mCRC